| |
| Emerging requirements for infectious disease IVD quality control material | |
| Quality Control Rapid Response in Pre-Pandemic Preparedness Showcasing a Synthetic H5N1 Genetic Template | |
| |
| Performance of High Risk HPV Single Analyte and Multiplex Panel External Quality Controls for Verification of Extended Genotyping on the BD Onclarity â„¢HPV Assay | |
| Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples and User Defined Quality Controls | |
| Abbott: Evaluation of Commercially Available HPV Panels with the Alinity m HR HPV Investigational Use Only (IUO) Assay | |
Abbott: Performance Characteristics of the Alinity m HR HPV Investigational Use Only (IUO) Assay and Comparison to the Cobas HPV 6800 Assay | |
Evaluating Diagnostic Workflows for HPV -Positive Oropharyngeal Squamous Cell Carcinoma Detection Using Simulated Specimens Mounted on Slides | |
| Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods | |
| Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel | |
| |
| Mycoplasma genitalium, Drug Resistance, Nucleic Acid Detection; Introducing a New External Quality Assessment Scheme | |
| Novel Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control | |
| Performance of NAAT that detect MGEN using Swab Quality Controls | |
| Evaluating the Performance of Emerging STI Point of Care Assays Using Novel, Room Temperature Stable CT/NG/TV/MG Positive Swab Quality Control Materials | |
| |
| Simulated swab specimens for whole workflow quality control of SARS-CoV-2 molecular diagnostic testing | |
| Advanced SARS-CoV-2 Variants of Concern (VOC) whole-genome materials for use as verification, external quality assessment (EQA) and prospective quality control samples | |
| Advanced SARS-CoV-2 nucleocapsid protein swab-based formulation for use as a cross-platform EQA sample and as a prospective Quality Control | |
| Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective quality controls | |
| Novel SARS-CoV-2 Full-Genome Material for Use in a Swab-Based Formulation as a Multi-Platform NAAT Quality Control | |
| Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab® for use as cross-platform compatible EQA samples and laboratory Quality Control | |
| |
| Novel Hepatitis C Virus External Quality Control That Is Stable at Ambient Temperature And Suitable For Use In Low-Resource Settings | |
| |
New External Quality Assessment Program for Laboratories that Detect H. pylori and Antimicrobial Resistant Markers Using Nucleic Acid Amplification Test Methods | |
| Aurevia: Neither Nor or Norovirus GI/GII? Good Consensus in International EQA Pilot Study for Norovirus Antigen Detection | |
| |
| FFPE HSV-1 and HSV-2 simulated tissue sections mounted on slides for use as prospective quality controls in IHC and qPCR workflows | |